Are you busy during this broadcast? See Broadcast #1 for an alternative time.
In immuno-oncology, companion diagnostics are used in conjunction with targeted drugs and therapies to identify patients who are likely to benefit from a specific treatment regimen or who may have increased risk for certain side effects. Join this webinar for a discussion of the integration of digital pathology, clinical trial design and tissue-based testing solutions for biomarker validation to quickly advance immuno-oncology therapies to pivotal clinical trial-scale studies.
Steven Anderson, Ph.D., Chief Scientific Officer, Covance Drug Development
Steven Anderson is senior vice president and chief scientific officer for Covance Drug Development. He has worked for LabCorp for 30 years and has held a variety of positions, including director of operations for ViroMed Laboratories, director of operations for Monogram Biosciences, director of operations for the Center for Molecular Biology and Pathology, director of operations for Integrated Oncology and Integrated Genetics, national director of research and development, and global head of LabCorp Clinical Trials. His research interests include Molecular Pathology and Oncology based biomarkers, and that work has resulted in the development and validation of multiple companion diagnostics and pharmacogenomic assays in clinical use today.
He holds a doctorate in genetics from Iowa State University and was an American Cancer Society postdoctoral fellow at the Waksman Institute of Microbiology at Rutgers University.Message Presenter
Gillian Livock, Vice President Corporate Business Development, Definiens
Gillian Livock joined Definiens in August 2017 with more than 20 years’ experience in clinical research with a focus on business development, alliance leadership and corporate business development.
In her previous role as VP, Business Development at Bioclinica, she was responsible for the European business and revenue growth of scientifically-driven services and technology-enabled solutions in clinical research. Before joining Bioclinica, Gillian served in the corporate team at ThermoFisher Scientific with a focus on promoting cross-divisional expertise and identifying products and services, across the organization, which could be integrated to deliver powerful customer solutions.
During her career, Gillian has managed and led successful global sales teams and created and delivered global alliances which have expanded services, successfully leveraged adjacent markets and increased revenue opportunities. Gillian has served as a board member of 3 companies and holds a Masters of Business Administration (MBA) in Life Sciences from the University of Dundee (UK).Message Presenter
Who Should Attend?
- Translational Scientists
- VP Oncology
- Directors of Immuno-Oncology Programs
- Directors of Companion Diagnostics
- Directors of Profiling
- Clinical Trial Managers/Directors/VP
What You Will Learn
Join this webinar to learn about:
- Strategies to accelerate immuno-oncology drug and diagnostic co-development
- Integrating multiplex immunohistochemistry, in situ hybridization and -omics data in early-stage clinical programs
- Utilizing digital pathology, machine learning and deep learning to create unique patient phenotypic profiles that support individualized diagnostic and therapy decisions
We improve patient lives by unlocking the tissue phenome.
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.
Definiens’ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.